TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases - Seite 2

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below.

Such forward looking statements include, but are not limited to, statements regarding the azer-cel allogeneic CD19 CAR T cell therapy program for all non-oncology indications. Factors that could cause our actual results to differ materially include the following: our ability to successfully and cost-effectively complete preclinical and clinical trials related to the CD19 CAR T cell therapy program; the risk that early clinical trial results that may have influenced our decision to undertake the development of the azer-cel allogeneic CD19 CAR T cell therapy program will not be reproduced in future studies; the risk that the company will not move forward with the development or commercialization of the azer-cel allogeneic CD19 CAR T cell therapy program for any non-oncology indications; the risk the IND is not filed or accepted by regulatory authorities in the timeline provided or at all; the risk that the azer-cel allogeneic CD19 CAR T cell therapy does not exhibit a clinical profile that is suitable for autoimmune disease; the risk that the equity investments in Precision may not appreciate in value, hold value, or have any value in the future. Further discussion about risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in our other filings with the U.S. Securities and Exchange Commission.